Advanced Tests for Heart Disease

ApoB, Lp(a) and Other Tests for Assessing Heart Disease Risk
Cardiovascular disease risk is not determined by a single blood test. Age, blood pressure, smoking, diabetes, family history and the standard lipid profile (LDL, HDL, triglycerides and total cholesterol) are assessed together. Tests such as ApoB, Lp(a) and hs-CRP may complement this assessment in some people; not everyone needs the same extensive panel.
What do the tests show, and who may be considered for testing?
| Test | What information does it provide? | When may it be considered? | Role in guidelines |
|---|---|---|---|
| ApoA-I (Apolipoprotein A-I) | The main protein in HDL particles. | May occasionally be requested in addition to the standard lipid profile for specific clinical assessments. | Not recommended on its own for routine cardiovascular screening or as a treatment target. |
| ApoB (Apolipoprotein B) | Reflects the number of particles associated with atherosclerosis, such as LDL, VLDL remnants and Lp(a). LDL cholesterol and particle number may not always align. | May be helpful in cases of elevated triglycerides, type 2 diabetes, cardiovascular-kidney-metabolic risks or an apparent discrepancy between LDL and overall risk; it may also help assess whether LDL and non-HDL targets have been reached during lipid-lowering treatment. | The 2026 ACC/AHA guideline considers ApoB measurement reasonable (Class 2a), particularly in people receiving treatment who have cardiovascular disease, metabolic risk, diabetes or high triglycerides. In people not receiving treatment, it may be considered (Class 2b) in selected circumstances. |
| ApoB/ApoA-I ratio | Expresses the ratio of atherosclerosis-associated ApoB particles to HDL-associated ApoA-I. | May provide additional information in certain specific assessments where risk is otherwise unclear. | Studies have found an association between this ratio and risk; however, it is not a standard guideline target used for routine screening or treatment decisions. Clinical decisions are mostly based on LDL-C, non-HDL-C and, when needed, ApoB. |
| Lp(a) – Lipoprotein(a) | A largely inherited lipoprotein. Elevated levels may increase cardiovascular risk independently of other risk factors. | Particularly relevant when there is a family history of heart attack or stroke at an early age, familial hypercholesterolaemia or premature vascular disease not explained by standard tests. | The 2026 ACC/AHA guideline recommends measurement at least once in a lifetime in all adults (Class 1). The 2025 ESC/EAS guideline also recommends considering measurement at least once in adulthood (Class IIa, level of evidence B). |
| hs-CRP (high-sensitivity CRP) | Measures low levels of inflammation in the blood. It does not indicate cardiovascular risk on its own or diagnose heart disease. | May provide additional risk information when calculated risk is borderline and the treatment decision is unclear. As levels may be elevated during infection or active inflammation, the result should be interpreted in the clinical context. | The 2026 ACC/AHA guideline considers its use reasonable to support treatment decisions in some adults at borderline risk if hs-CRP is ≥2 mg/L on two separate measurements and there is no other cause for the elevation (Class 2a). ESC/EAS also considers persistently elevated levels >2 mg/L a risk modifier in selected individuals. |
| Homocysteine | A substance involved in amino acid metabolism. Elevated levels may be associated with B12/folate deficiency or certain other conditions. | Generally not requested for routine cardiovascular screening. A doctor may consider it in specific situations, such as unexplained vascular disease at a very young age or suspected rare homocystinuria. | Routine screening is not recommended because lowering elevated homocysteine with vitamins has not been shown to reduce the risk of heart attack or stroke. |
How should the results be interpreted?
Lp(a), ApoB and hs-CRP results do not diagnose heart disease on their own. A doctor assesses the results alongside standard cholesterol tests and the person's overall risk profile. Particularly for Lp(a), there is no exact conversion between mg/dL and nmol/L that applies to every measurement, so the unit used by the laboratory must be taken into account.
The basic approach to assessing cardiovascular risk includes medical history, blood pressure, a standard lipid profile, blood glucose and, when needed, a clinical examination. Additional tests are selected if they will genuinely help guide a change in clinical decisions. Click to explore advanced cardiac tests. Click for a Heart Checkup.
